496 related articles for article (PubMed ID: 33960680)
21. RGS16 promotes glioma progression and serves as a prognostic factor.
Huang R; Li G; Zhao Z; Zeng F; Zhang K; Liu Y; Wang K; Hu H
CNS Neurosci Ther; 2020 Aug; 26(8):791-803. PubMed ID: 32319728
[TBL] [Abstract][Full Text] [Related]
22. A novel pyroptosis-related gene signature predicts the prognosis of glioma through immune infiltration.
Zhang M; Cheng Y; Xue Z; Sun Q; Zhang J
BMC Cancer; 2021 Dec; 21(1):1311. PubMed ID: 34876094
[TBL] [Abstract][Full Text] [Related]
23.
Qu S; Liu J; Wang H
Front Immunol; 2021; 12():648416. PubMed ID: 33889156
[TBL] [Abstract][Full Text] [Related]
24. Molecular and clinical characterization of PARP9 in gliomas: A potential immunotherapeutic target.
Xu H; Chai S; Wang Y; Wang J; Xiao D; Li J; Xiong N
CNS Neurosci Ther; 2020 Aug; 26(8):804-814. PubMed ID: 32678519
[TBL] [Abstract][Full Text] [Related]
25. Transforming growth factor beta induced (TGFBI) is a potential signature gene for mesenchymal subtype high-grade glioma.
Pan YB; Zhang CH; Wang SQ; Ai PH; Chen K; Zhu L; Sun ZL; Feng DF
J Neurooncol; 2018 Apr; 137(2):395-407. PubMed ID: 29294230
[TBL] [Abstract][Full Text] [Related]
26. Identification of three tumor antigens and immune subtypes for mRNA vaccine development in diffuse glioma.
Zhou Q; Yan X; Zhu H; Xin Z; Zhao J; Shen W; Yin W; Guo Y; Xu H; Zhao M; Liu W; Jiang X; Ren C
Theranostics; 2021; 11(20):9775-9790. PubMed ID: 34815785
[No Abstract] [Full Text] [Related]
27. Elevated TYROBP expression predicts poor prognosis and high tumor immune infiltration in patients with low-grade glioma.
Lu J; Peng Y; Huang R; Feng Z; Fan Y; Wang H; Zeng Z; Ji Y; Wang Y; Wang Z
BMC Cancer; 2021 Jun; 21(1):723. PubMed ID: 34162355
[TBL] [Abstract][Full Text] [Related]
28. Bioinformatic Profiling Identifies a Glucose-Related Risk Signature for the Malignancy of Glioma and the Survival of Patients.
Zhao S; Cai J; Li J; Bao G; Li D; Li Y; Zhai X; Jiang C; Fan L
Mol Neurobiol; 2017 Dec; 54(10):8203-8210. PubMed ID: 27900679
[TBL] [Abstract][Full Text] [Related]
29. Correlation of alteration of HLA-F expression and clinical characterization in 593 brain glioma samples.
Feng E; Liang T; Wang X; Du J; Tang K; Wang X; Wang F; You G
J Neuroinflammation; 2019 Feb; 16(1):33. PubMed ID: 30755240
[TBL] [Abstract][Full Text] [Related]
30. Systematic identification, development, and validation of prognostic biomarkers involving the tumor-immune microenvironment for glioblastoma.
Zhao B; Wang Y; Wang Y; Chen W; Liu PH; Kong Z; Dai C; Wang Y; Ma W
J Cell Physiol; 2021 Jan; 236(1):507-522. PubMed ID: 32572951
[TBL] [Abstract][Full Text] [Related]
31. Enhanced B7-H4 expression in gliomas with low PD-L1 expression identifies super-cold tumors.
Chen D; Li G; Ji C; Lu Q; Qi Y; Tang C; Xiong J; Hu J; Yasar FBA; Zhang Y; Hoon DSB; Yao Y; Zhou L
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32457124
[TBL] [Abstract][Full Text] [Related]
32. Aberrant expression of RSK1 characterizes high-grade gliomas with immune infiltration.
M Hajj GN; da Silva FF; de Bellis B; Lupinacci FCS; Bellato HM; Cruz JR; Segundo CNC; Faquini IV; Torres LC; Sanematsu PI; Begnami MD; Martins VR; Roffé M
Mol Oncol; 2020 Jan; 14(1):159-179. PubMed ID: 31701625
[TBL] [Abstract][Full Text] [Related]
33. The CXCL Family Contributes to Immunosuppressive Microenvironment in Gliomas and Assists in Gliomas Chemotherapy.
Wang Z; Liu Y; Mo Y; Zhang H; Dai Z; Zhang X; Ye W; Cao H; Liu Z; Cheng Q
Front Immunol; 2021; 12():731751. PubMed ID: 34603309
[TBL] [Abstract][Full Text] [Related]
34. PLEKHA4 Is a Prognostic Biomarker and Correlated with Immune Infiltrates in Glioma.
Zhang W; Li L; Bian PP; Luo QP; Xiong ZT
Biomed Res Int; 2023; 2023():4504474. PubMed ID: 36714030
[TBL] [Abstract][Full Text] [Related]
35. A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients.
Zhu Z; Lan Y; Wang L; Ge J; Wang J; Liu F; He Z; Zhang H; Luo M; Lin D; Tan Y; Xu Y; Luo T
BMC Cancer; 2020 Nov; 20(1):1072. PubMed ID: 33167941
[TBL] [Abstract][Full Text] [Related]
36. Serine Incorporator 2 (SERINC2) Expression Predicts an Unfavorable Prognosis of Low-Grade Glioma (LGG): Evidence from Bioinformatics Analysis.
Qi C; Lei L; Hu J; Wang G; Liu J; Ou S
J Mol Neurosci; 2020 Oct; 70(10):1521-1532. PubMed ID: 32642801
[TBL] [Abstract][Full Text] [Related]
37. ITGB2 as a prognostic indicator and a predictive marker for immunotherapy in gliomas.
Xu H; Zhang A; Han X; Li Y; Zhang Z; Song L; Wang W; Lou M
Cancer Immunol Immunother; 2022 Mar; 71(3):645-660. PubMed ID: 34313821
[TBL] [Abstract][Full Text] [Related]
38. ZEB1 expression is increased in IDH1-mutant lower-grade gliomas.
Nesvick CL; Zhang C; Edwards NA; Montgomery BK; Lee M; Yang C; Wang H; Zhu D; Heiss JD; Merrill MJ; Ray-Chaudhury A; Zhuang Z
J Neurooncol; 2016 Oct; 130(1):111-122. PubMed ID: 27568035
[TBL] [Abstract][Full Text] [Related]
39. Identification of Hub Gene GRIN1 Correlated with Histological Grade and Prognosis of Glioma by Weighted Gene Coexpression Network Analysis.
Yang A; Wang X; Hu Y; Shang C; Hong Y
Biomed Res Int; 2021; 2021():4542995. PubMed ID: 34840971
[TBL] [Abstract][Full Text] [Related]
40. Profiles of immune-related genes and immune cell infiltration in the tumor microenvironment of diffuse lower-grade gliomas.
Deng X; Lin D; Zhang X; Shen X; Yang Z; Yang L; Lu X; Yu L; Zhang N; Lin J
J Cell Physiol; 2020 Oct; 235(10):7321-7331. PubMed ID: 32162312
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]